

CORRECTION



Correction to: Prognostic role of *EGFR* gene copy number and *KRAS* mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy

C. Bengala, S. Bettelli, F. Bertolini, G. Sartori, A. Fontana, N. Malavasi, R. Depenni, S. Zironi, C. Del Giovane, G. Luppi and P. F. Conte

© The Author(s), under exclusive licence to Springer Nature Limited 2024

British Journal of Cancer (2024) 131:954; <https://doi.org/10.1038/s41416-024-02790-9>

Correction to: *British Journal of Cancer* Prognostic role of *EGFR* gene copy number and *KRAS* mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy; <https://doi.org/10.1038/sj.bjc.6605853>; Article published online 14 September 2010

Following the original publication of the article, the authors identified an error in Table 2. Under *KRAS* status 'Mutated', TRG 3–4 originally read 51 (8.5); this should read 5 (18.5).

The correction does not have any effect on the results or conclusions of the paper.

Table 2. *EGFR* gene copy number, *KRAS* status, pathological response and downstaging

	<i>EGFR</i> /nuclei ratio			CEP7 polisomy			<i>K-RAS</i> status		
	< 2.9	≥2.9	<i>p</i> value	<50 %	≥50 %	<i>p</i> value	Wild type	Mutated	<i>p</i> value
Pathological response									
Assessable patients, <i>n</i>	113	27		110	30		114	27	
TRG 4, <i>n</i> , (%)	15 (13.3)	6 (22.2)	0.19	14 (12.7)	7 (23.3)	0.13	19 (16.7)	2 (7.4)	0.18
TRG 3–4, <i>n</i> , (%)	36 (31.9)	9 (33.3)	0.53	36 (32.7)	9 (30.0)	0.48	40 (35.1)	5 (18.5)	0.07
Downstaging									
Assessable patients, <i>n</i>	109	29		105	33		111	28	
Downstaging, <i>n</i> , (%)	65 (59.6)	19 (65.5)	0.36	68 (64.8)	16 (48.5)	0.07	69 (62.2)	16 (57.1)	0.39

The original article has been corrected.